Cargando…

Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA‐3 TriaL (VITAL)

Although supplemental vitamin D is used to promote bone health in the general population, data from randomized controlled trials (RCTs) have been inconsistent. We determined whether daily, vitamin D(3) supplementation improves bone mineral density (BMD) and/or structure. VITamin D and OmegA‐3 TriaL...

Descripción completa

Detalles Bibliográficos
Autores principales: LeBoff, Meryl S, Chou, Sharon H, Murata, Elle M, Donlon, Catherine M, Cook, Nancy R, Mora, Samia, Lee, I‐Min, Kotler, Gregory, Bubes, Vadim, Buring, Julie E, Manson, JoAnn E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217747/
https://www.ncbi.nlm.nih.gov/pubmed/31923341
http://dx.doi.org/10.1002/jbmr.3958
_version_ 1783532651708153856
author LeBoff, Meryl S
Chou, Sharon H
Murata, Elle M
Donlon, Catherine M
Cook, Nancy R
Mora, Samia
Lee, I‐Min
Kotler, Gregory
Bubes, Vadim
Buring, Julie E
Manson, JoAnn E
author_facet LeBoff, Meryl S
Chou, Sharon H
Murata, Elle M
Donlon, Catherine M
Cook, Nancy R
Mora, Samia
Lee, I‐Min
Kotler, Gregory
Bubes, Vadim
Buring, Julie E
Manson, JoAnn E
author_sort LeBoff, Meryl S
collection PubMed
description Although supplemental vitamin D is used to promote bone health in the general population, data from randomized controlled trials (RCTs) have been inconsistent. We determined whether daily, vitamin D(3) supplementation improves bone mineral density (BMD) and/or structure. VITamin D and OmegA‐3 TriaL (VITAL) is a double‐blind, placebo‐controlled RCT of supplemental vitamin D(3) (2000 IU/d) and/or omega‐3 fatty acids (1 g/d) in 25,871 adults nationwide. This ancillary study included a subcohort of 771 participants (men ≥50 and women ≥55 years; not taking bone active medications) evaluated at baseline and at 2‐year follow‐up (89% retention). Total 25(OH)D levels were measured by liquid chromatography tandem mass spectrometry (Quest Diagnostics, San Juan Capistrano, CA, USA). Free 25(OH)D (FVD) levels were measured using the ELISA assay by Future Diagnostics Solutions BV (Wijchen, Netherlands). Primary endpoints were 2‐year changes in areal (a) BMD at the spine, hip, and whole body determined by dual‐energy X‐ray absorptiometry (DXA). Secondary endpoints were 2‐year changes in volumetric (v) BMD and cortical thickness at the radius and tibia assessed by peripheral quantitative computed tomography. Supplemental vitamin D(3) versus placebo had no effect on 2‐year changes in aBMD at the spine (0.33% versus 0.17%; p = 0.55), femoral neck (−0.27% versus −0.68%; p = 0.16), total hip (−0.76% versus −0.95%; p = 0.23), or whole body (−0.22% versus −0.15%; p = 0.60), or on measures of bone structure. Effects did not vary by sex, race/ethnicity, body mass index, or 25(OH)D levels. Among participants with baseline FVD levels below the median (<14.2 pmol/L), there was a slight increase in spine aBMD (0.75% versus 0%; p = 0.043) and attenuation in loss of total hip aBMD (−0.42% versus −0.98%; p = 0.044) with vitamin D(3). Whether baseline FVD levels help to identify those more likely to benefit from supplementation warrants further study. Supplemental vitamin D(3) versus placebo for 2 years in general healthy adults not selected for vitamin D insufficiency did not improve BMD or structure. © 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
format Online
Article
Text
id pubmed-7217747
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-72177472021-05-01 Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA‐3 TriaL (VITAL) LeBoff, Meryl S Chou, Sharon H Murata, Elle M Donlon, Catherine M Cook, Nancy R Mora, Samia Lee, I‐Min Kotler, Gregory Bubes, Vadim Buring, Julie E Manson, JoAnn E J Bone Miner Res Original Articles Although supplemental vitamin D is used to promote bone health in the general population, data from randomized controlled trials (RCTs) have been inconsistent. We determined whether daily, vitamin D(3) supplementation improves bone mineral density (BMD) and/or structure. VITamin D and OmegA‐3 TriaL (VITAL) is a double‐blind, placebo‐controlled RCT of supplemental vitamin D(3) (2000 IU/d) and/or omega‐3 fatty acids (1 g/d) in 25,871 adults nationwide. This ancillary study included a subcohort of 771 participants (men ≥50 and women ≥55 years; not taking bone active medications) evaluated at baseline and at 2‐year follow‐up (89% retention). Total 25(OH)D levels were measured by liquid chromatography tandem mass spectrometry (Quest Diagnostics, San Juan Capistrano, CA, USA). Free 25(OH)D (FVD) levels were measured using the ELISA assay by Future Diagnostics Solutions BV (Wijchen, Netherlands). Primary endpoints were 2‐year changes in areal (a) BMD at the spine, hip, and whole body determined by dual‐energy X‐ray absorptiometry (DXA). Secondary endpoints were 2‐year changes in volumetric (v) BMD and cortical thickness at the radius and tibia assessed by peripheral quantitative computed tomography. Supplemental vitamin D(3) versus placebo had no effect on 2‐year changes in aBMD at the spine (0.33% versus 0.17%; p = 0.55), femoral neck (−0.27% versus −0.68%; p = 0.16), total hip (−0.76% versus −0.95%; p = 0.23), or whole body (−0.22% versus −0.15%; p = 0.60), or on measures of bone structure. Effects did not vary by sex, race/ethnicity, body mass index, or 25(OH)D levels. Among participants with baseline FVD levels below the median (<14.2 pmol/L), there was a slight increase in spine aBMD (0.75% versus 0%; p = 0.043) and attenuation in loss of total hip aBMD (−0.42% versus −0.98%; p = 0.044) with vitamin D(3). Whether baseline FVD levels help to identify those more likely to benefit from supplementation warrants further study. Supplemental vitamin D(3) versus placebo for 2 years in general healthy adults not selected for vitamin D insufficiency did not improve BMD or structure. © 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research. John Wiley & Sons, Inc. 2020-01-30 2020-05 /pmc/articles/PMC7217747/ /pubmed/31923341 http://dx.doi.org/10.1002/jbmr.3958 Text en © 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
LeBoff, Meryl S
Chou, Sharon H
Murata, Elle M
Donlon, Catherine M
Cook, Nancy R
Mora, Samia
Lee, I‐Min
Kotler, Gregory
Bubes, Vadim
Buring, Julie E
Manson, JoAnn E
Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA‐3 TriaL (VITAL)
title Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA‐3 TriaL (VITAL)
title_full Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA‐3 TriaL (VITAL)
title_fullStr Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA‐3 TriaL (VITAL)
title_full_unstemmed Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA‐3 TriaL (VITAL)
title_short Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA‐3 TriaL (VITAL)
title_sort effects of supplemental vitamin d on bone health outcomes in women and men in the vitamin d and omega‐3 trial (vital)
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217747/
https://www.ncbi.nlm.nih.gov/pubmed/31923341
http://dx.doi.org/10.1002/jbmr.3958
work_keys_str_mv AT leboffmeryls effectsofsupplementalvitamindonbonehealthoutcomesinwomenandmeninthevitamindandomega3trialvital
AT chousharonh effectsofsupplementalvitamindonbonehealthoutcomesinwomenandmeninthevitamindandomega3trialvital
AT murataellem effectsofsupplementalvitamindonbonehealthoutcomesinwomenandmeninthevitamindandomega3trialvital
AT donloncatherinem effectsofsupplementalvitamindonbonehealthoutcomesinwomenandmeninthevitamindandomega3trialvital
AT cooknancyr effectsofsupplementalvitamindonbonehealthoutcomesinwomenandmeninthevitamindandomega3trialvital
AT morasamia effectsofsupplementalvitamindonbonehealthoutcomesinwomenandmeninthevitamindandomega3trialvital
AT leeimin effectsofsupplementalvitamindonbonehealthoutcomesinwomenandmeninthevitamindandomega3trialvital
AT kotlergregory effectsofsupplementalvitamindonbonehealthoutcomesinwomenandmeninthevitamindandomega3trialvital
AT bubesvadim effectsofsupplementalvitamindonbonehealthoutcomesinwomenandmeninthevitamindandomega3trialvital
AT buringjuliee effectsofsupplementalvitamindonbonehealthoutcomesinwomenandmeninthevitamindandomega3trialvital
AT mansonjoanne effectsofsupplementalvitamindonbonehealthoutcomesinwomenandmeninthevitamindandomega3trialvital